These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Tré-Hardy M; Nagant C; El Manssouri N; Vanderbist F; Traore H; Vaneechoutte M; Dehaye JP Antimicrob Agents Chemother; 2010 Oct; 54(10):4409-15. PubMed ID: 20696878 [TBL] [Abstract][Full Text] [Related]
26. Pinto RM; Monteiro C; Costa Lima SA; Casal S; Van Dijck P; Martins MCL; Nunes C; Reis S ACS Appl Mater Interfaces; 2021 Sep; 13(36):42329-42343. PubMed ID: 34464076 [TBL] [Abstract][Full Text] [Related]
27. Distribution and Inhibition of Liposomes on Staphylococcus aureus and Pseudomonas aeruginosa Biofilm. Dong D; Thomas N; Thierry B; Vreugde S; Prestidge CA; Wormald PJ PLoS One; 2015; 10(6):e0131806. PubMed ID: 26125555 [TBL] [Abstract][Full Text] [Related]
28. D-amino acids enhance the activity of antimicrobials against biofilms of clinical wound isolates of Staphylococcus aureus and Pseudomonas aeruginosa. Sanchez CJ; Akers KS; Romano DR; Woodbury RL; Hardy SK; Murray CK; Wenke JC Antimicrob Agents Chemother; 2014 Aug; 58(8):4353-61. PubMed ID: 24841260 [TBL] [Abstract][Full Text] [Related]
29. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277 [TBL] [Abstract][Full Text] [Related]
30. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Smith S; Waters V; Jahnke N; Ratjen F Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436 [TBL] [Abstract][Full Text] [Related]
31. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972 [TBL] [Abstract][Full Text] [Related]
32. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections. Bala A; Kumar R; Harjai K J Med Microbiol; 2011 Mar; 60(Pt 3):300-306. PubMed ID: 21127154 [TBL] [Abstract][Full Text] [Related]
34. Attenuation of Pseudomonas aeruginosa biofilm formation by Vitexin: A combinatorial study with azithromycin and gentamicin. Das MC; Sandhu P; Gupta P; Rudrapaul P; De UC; Tribedi P; Akhter Y; Bhattacharjee S Sci Rep; 2016 Mar; 6():23347. PubMed ID: 27000525 [TBL] [Abstract][Full Text] [Related]
35. Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa. Soren O; Rineh A; Silva DG; Cai Y; Howlin RP; Allan RN; Feelisch M; Davies JC; Connett GJ; Faust SN; Kelso MJ; Webb JS J Antimicrob Chemother; 2020 Jan; 75(1):117-125. PubMed ID: 31682251 [TBL] [Abstract][Full Text] [Related]
36. Improved effect of amikacin-loaded poly(D,L-lactide-co-glycolide) nanoparticles against planktonic and biofilm cells of Pseudomonas aeruginosa. Sabaeifard P; Abdi-Ali A; Gamazo C; Irache JM; Soudi MR J Med Microbiol; 2017 Mar; 66(2):137-148. PubMed ID: 28260589 [TBL] [Abstract][Full Text] [Related]
37. Albumin-coated pH-responsive dimeric prodrug-based nano-assemblies with high biofilm eradication capacity. Li X; Li W; Li K; Chen X; Wang C; Qiao M; Hong W Biomater Sci; 2023 Jan; 11(3):1031-1041. PubMed ID: 36545821 [No Abstract] [Full Text] [Related]